Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Apr 13, 2022 5:11am
75 Views
Post# 34599235

RE:RE:RE:RE:A nibble

RE:RE:RE:RE:A nibble
MrMugsy wrote: Goodman lent Appili Therapeutics a couple million dollars at 8.5% through his holding company.
He also received rights to future drugs in Canada, LATAM and Israel.

I checked on this because it worried me ... thought that GUD was potentially competing against Goodman.  Not so as per Samira ... she didn't want the deal.

She's looking for better guarantees.
She's probably also looking for faster-to-market products right now.  IMO.

Goodman tabled an offer and Appili accepted the terms. 

------------------------


gudisgood wrote:
MrMugsy wrote: I checked in with Samira on this deal back in March.
She chose to take a pass on this one - sounds like she didn't care for the risk profile.
Then, Goodman offered to lend.
------------------------------------------
If the assets ever come to market, I'm guessing Goodman would liikely offer rights sale to us.
 


Hey MrMugsy, can you explain this a little bit more? What are we talking about here? :D




Ahh okay, thanks. The opening post of this thread was about Goodman buying a tiny amount of Knight stock -- therefore I was confused about what you meant. But it's nice to know about the Appili deal. And quite interesting to know that it's something Goodman found acceptable but Samira didn't. :)

<< Previous
Bullboard Posts
Next >>